Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-kappaB.
Cholangiocarcinoma (CCA) is a major cause of cancer deaths in northeast Thailand. It is aggressive, highly metastatic, and responds poorly to traditional chemotherapy. We demonstrated the potential for Cepharanthine (CEP), a biscoclaurine alkaloid extracted from Stephania cepharantha, to treat CCA. CEP significantly inhibited growth of human CCA cell lines in a dose- and time-dependent manner, regardless of the histologic type of tumor origin. Increasing cell apoptosis via caspase-3 and capase-9 activation was demonstrated in CEP-treated cells. We found that CEP controlled the growth of CCA cells through nuclear factor-kappa B (NF-kappaB) inactivation by inhibiting nuclear translocation. CEP treatment effectively reduced tumor size in CCA-inoculated mice without serious side effects. CEP also increased cell apoptosis in primary histocultures of CCA patients' tissues; this was demonstrated by immunohistochemistry using TUNEL staining. Our results suggest that CEP possesses therapeutic potential against human CCA.
Seubwai
Wunchana
W
Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Vaeteewoottacharn
Kulthida
K
Hiyoshi
Masateru
M
Suzu
Shinya
S
Puapairoj
Anucha
A
Wongkham
Chairisi
C
Okada
Seiji
S
Wongkham
Sopit
S
D000470:Alkaloids / Q000302:isolation & purification / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D044182:Benzylisoquinolines / Q000302:isolation & purification / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D001653:Bile Ducts, Intrahepatic; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D053938:DNA Fragmentation / Q000187:drug effects; D006801:Humans; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D008517:Phytotherapy; D031607:Stephania / Q000737:chemistry; D013785:Thailand / Q000453:epidemiology; D052117:Benzodioxoles
D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; D044182:Benzylisoquinolines; D016328:NF-kappa B; C006947:cepharanthine; D052117:Benzodioxoles
Anticancer Res. 2009 Apr;29(4):1263-70
19414373
Life Sci. 2007 Feb 27;80(12):1073-9
17204293
Gan To Kagaku Ryoho. 2001 Oct;28(11):1515-8
11707968
Nihon Geka Hokan. 1997 May 1;66(2):71-7
9796252
Int J Oncol. 2008 Oct;33(4):807-14
18813795
Hepatology. 2003 May;37(5):961-9
12717374
Nat Rev Cancer. 2002 Apr;2(4):301-10
12001991
Am J Gastroenterol. 2004 Mar;99(3):523-6
15056096
Gan To Kagaku Ryoho. 1990 Jun;17(6):1195-200
2190537
Int J Oncol. 2004 Mar;24(3):635-45
14767548
Methods Find Exp Clin Pharmacol. 1998 Mar;20(2):87-97
9604850
Lab Invest. 2003 Nov;83(11):1657-67
14615419
Int J Hematol. 2008 Dec;88(5):476-482
19039627
Nature. 1970 Aug 15;227(5259):680-5
5432063
Trends Biochem Sci. 1997 Aug;22(8):299-306
9270303
Int J Cancer. 2009 Aug 1;125(3):565-76
19358267
Int J Oncol. 2007 Oct;31(4):761-8
17786306
Oncologist. 2004;9(1):43-57
14755014
Oncogene. 1995 Sep 7;11(5):999-1003
7675461
Int J Cancer. 2006 Sep 1;119(5):1067-72
16570287
Cancer Sci. 2005 Jun;96(6):372-6
15958061
Cell Death Differ. 2006 May;13(5):748-58
16498458
Int J Cancer. 2009 Sep 15;125(6):1464-72
19521981
Anticancer Res. 2003 Mar-Apr;23(2B):1441-8
12820407
Prostate. 2002 Aug 1;52(3):183-200
12111695
J Dermatol. 1991 Nov;18(11):643-8
1800530
Gan To Kagaku Ryoho. 1990 Apr;17(4 Pt 1):645-8
2108613
Anticancer Res. 2004 Mar-Apr;24(2B):675-81
15161011
FEBS Lett. 2006 Jan 23;580(2):703-10
16412424
Gan To Kagaku Ryoho. 1992 May;19(5):647-52
1316101
Hepatology. 2006 Oct;44(4):1025-38
17006947
Phytother Res. 2009 Apr;23(4):587-90
19107844
Anticancer Res. 1992 Sep-Oct;12(5):1377-82
1444194
Arthritis Rheum. 2002 Jun;46(6):1585-94
12115190
Cell Signal. 2002 Jun;14(6):509-15
11897491